2024 年第 3 期 第 19 卷

自拟补肺化瘀方辅助化疗治疗晚期非小细胞肺癌患者的效果观察

Observation of effect on self-made Bufei Huayu prescription as adjuvant chemotherapy in the treatment of patients with advanced non-small cell lung cancer

作者：宋倩男1张俐佳2闫珺2孙姮2刘松江2

英文作者：Song Qiannan1 Zhang Lijia2 Yan Jun2 Sun Heng2 Liu Songjiang2

单位：1黑龙江中医药大学研究生院，哈尔滨150040；2黑龙江中医药大学附属第一医院肿瘤科，哈尔滨150040

英文单位：1Graduate School of Heilongjiang University of Chinese Medicine Harbin 150040 China; 2Department of Oncology First Affiliated Hospital Heilongjiang University of Chinese Medicine Harbin 150040 China

关键词：晚期非小细胞肺癌；补肺化瘀方；化疗；免疫功能；高凝状态

英文关键词：Advancednon-smallcelllungcancer;BufeiHuayuprescription;Chemotherapy;Immunefunction;Stateofhypercoagulability

• 摘要：

• 目的 探讨自拟补肺化瘀方辅助化疗治疗晚期非小细胞肺癌（NSCLC）患者的效果及对患者免疫功能和高凝状态的影响。方法 选取2019年10月至2021年9月黑龙江中医药大学附属第一医院收治的96例晚期NSCLC患者，按照随机数字表法分为对照组和观察组，各48例。对照组实施单纯化疗；观察组在对照组基础上联合自拟补肺化瘀方辅助治疗。对2组患者的NSCLC控制情况进行比较分析，并针对2组患者的血清肿瘤标志物和免疫功能指标进行检测分析，同时记录不良反应发生情况。比较2组患者治疗前后血小板计数（PLT）、血小板聚集率（MAR）、纤维蛋白原（FIB）和D-二聚体水平。结果 观察组疾病控制率高于对照组［77.1%（37/48）比56.2%（27/48）］（P=0.008）。治疗后，2组患者的血清肿瘤标志物（癌胚抗原、神经元特异性烯醇化酶、细胞角蛋白19片段）水平均明显低于治疗前，且观察组均低于对照组，差异均有统计学意义（均P＜0.05）。治疗后，2组CD+3、CD+4/CD+8比值均高于治疗前，且观察组均高于对照组，差异均有统计学意义（均P＜0.05）。治疗后，观察组患者的PLT、MAR、FIB和D-二聚体水平均低于治疗前，且观察组均低于对照组，差异均有统计学意义（均P＜0.05）。观察组不良反应发生率低于对照组［10.4%(5/48)比31.2%(15/48)］(P＜0.001)。结论 自拟补肺化瘀方辅助化疗治疗晚期NSCLC的效果显著，可控制疾病进展，改善患者免疫功能和血液高凝状态，减少化疗期间的不良反应。

• Objective To explore the effect on self-made Bufei Huayu prescription as adjuvant chemotherapy in the treatment of patients with advanced non-small cell lung cancer (NSCLC) and the effect on the immune function and state of hypercoagulability. Methods A total of 96 patients with advanced NSCLC in First Affiliated Hospital, Heilongjiang University of Chinese Medicine from October 2019 to September 2021 were selected and divided into control group and observation group according to random number table method, with 48 cases in each group. The control group was given chemotherapy alone, and the observation group was combined with self-made Bufei Huayu prescription for adjuvant therapy on the basis of the control group. The control of NSCLC in the two groups was compared and analyzed, and the serum tumor markers and immune function indexes of the two groups were detected and analyzed, and the occurrence of adverse reactions was recorded. Platelet, platelet aggregation rate(MAR), fibrinogen (FIB) and D-dimer levels were compared between two groups before and after treatment. Results The disease control rate in the observation group was higher than that in the control group ［77.1%(37/48) vs 56.2%(27/48)］(P=0.008). After treatment, the levels of serum tumor markers (carcinoembryonic antigen, neuron specific enolase, cell Keratin 19 fragment) in two groups were significantly lower than those before treatment, and in observation group were lower than those in control group(all P＜0.05). After treatment, the levels of CD+3 and ratios of CD+4/CD+8 in both groups were higher than those before treatment, and in the observation group were higher than those in control group(all P＜0.05). After treatment, the levels of platelet, MAR, FIB and D-dimer in observation group were lower than those before treatment, and the levels in observation group were lower than those in control group(all P＜0.05). The incidence of adverse reactions in observation group was lower than that in control group ［10.4%(5/48) vs 31.2%(15/48)］(P＜0.001). Conclusion Self-made Bufei Huayu prescription has significant effect in the treatment of advanced NSCLC, which can control the progression of the disease, improve the immune function of patients, significantly improve the state of hypercoagulability of patients, and reduce the occurrence of adverse reactions during chemotherapy.